The present invention relates to an antibody against CD127, which is the alpha chain of interleukin 7 (IL-7) receptor (IL-7R), having antagonistic properties against IL-7-IL-7R interaction, and CD127 positive cells Relates to antibodies that can exhibit cytotoxic activity against, but also do not increase dendritic cell maturation (DC) induced by TSLP, a cytokine that uses CD127 as part of its receptor. Alternatively or additionally, these antibodies do not induce CD127 internalization and / or inhibit IL7-induced CD127 internalization. According to another aspect of the present invention, there is provided an antibody that recognizes a human CD127 epitope comprising a sequence derived from the 2b site of CD127, in particular the epitope comprises a human CD127 sequence of domain D1 and a human CD127 of the 2b site of CD127. In particular, the epitope is derived from at least one sequence from D1 comprising SEQ ID NO: 115 (particularly comprising SEQ ID NO: 110) and / or SEQ ID NO: 111 and / or a 2b site comprising the sequence of SEQ ID NO: 116 And optionally also SEQ ID NO: 117 (particularly including SEQ ID NO: 111). The antibodies of the present invention, inter alia, increase dendritic cell maturation, more precisely, upregulation of dendritic cell costimulatory molecules, when the IL-7 signaling pathway contributes to the pathogenesis associated with lymphocyte production. Is preferred for use to ameliorate conditions resulting from the pathogenesis diagnosed in human patients. [Selection figure] None本発明は、インターロイキン７（ＩＬ－７）受容体（ＩＬ－７Ｒ）のアルファ鎖であるＣＤ１２７に対する抗体であって、ＩＬ－７－ＩＬ－７Ｒ相互作用に対するアンタゴニスト特性を有し、ＣＤ１２７陽性細胞に対する細胞傷害活性を提示し得るが、同じくその受容体の一部としてＣＤ１２７を用いるサイトカインであるＴＳＬＰによって誘導される樹状細胞の成熟（ＤＣ）を増大させない、抗体に関する。代わりに、又はさらに、これらの抗体は、ＣＤ１２７の内在化を誘導せず、及び／又はＩＬ７誘導性のＣＤ１２７内在化を阻害する。本発明の別の態様によれば、ＣＤ１２７の２ｂ部位由来の配列を含むヒトＣＤ１２７エピトープを認識する抗体が提供され、特に、該エピトープは、ドメインＤ１のヒトＣＤ１２７配列及びＣＤ１２７の２ｂ部位のヒトＣＤ１２７配列を含み、特に、該エピトープは、配列番号１１５（特に、配列番号１１０を含む）及び／もしくは配列番号１１１を含むＤ１由来の少なくとも１つの配列並びに／又は配列番号１１６の配列を含む２ｂ部位由来の配列を含み、かつ任意に、配列番号１１７（特に、配
